Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer

This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma. The name of the intervention(s) involved in this study are: Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.

Inclusion Criteria: * Patients must have the ability to understand and the willingness to sign a written informed consent document. * Participants must have confirmed or suspected lung cancer or mesothelioma or other intrathoracic malignancy, and are planned for surgical resection of the tumor as part of their standard clinical care. * Participants must be 18 years of age or older. * Participants must be evaluated by a medical oncologist or surgeon who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease. * Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures. * Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Patients must have absolute neutrophil count ≥1,000/mcL, platelets ≥120,000/mcL, PT (INR) 1.5 and PTT \